Memantina Tecnigen

Memantine Hydrochloride, the active ingredient in Memantina Tecnigen, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat Alzheimer’s disease in adult patients, helping to preserve cognition and functional abilities.

GNH USA supplies Memantina Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Tecnigen is an NMDA receptor antagonist indicated for Alzheimer’s disease and related cognitive disorders.

- Alzheimer’s disease (moderate to severe): improves cognition and daily functioning. - Alzheimer’s disease (mild to moderate) as adjunct therapy: may support cognitive performance when combined with cholinesterase inhibitors. - Behavioral disturbances in Alzheimer’s disease: may reduce agitation and aggression.

Common Side Effects: - Dizziness: mild to moderate vertigo. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Confusion: occasional disorientation. - Fatigue: feeling of tiredness. - Hypertension: mild increase in blood pressure.

Serious or Rare Side Effects: - Seizures: rare convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Suicidal thoughts: emergence of depressive ideation. - Psychosis: hallucinations or delusional thinking.

Memantina Tecnigen should be used with caution in specific clinical situations.

- Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes regularly. - Cardiovascular disease: observe blood pressure and heart rhythm. - Concomitant NMDA agonists: avoid combined use due to antagonistic effects. - Pregnancy: risk unknown; use only if potential benefit justifies the risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Memantina Tecnigen may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: concurrent NMDA agonist may reduce efficacy. - Ketamine: additive NMDA antagonism may increase neurotoxicity risk. - Strong CYP450 inhibitors (e.g., quinidine): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate cognitive side effects. - Diuretics: monitor electrolyte balance and renal function. - CNS depressants (e.g., benzodiazepines): may increase sedation. - Antihypertensives: watch for additive blood pressure effects.